PMID- 33386257
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1437-7780 (Electronic)
IS  - 1341-321X (Linking)
VI  - 27
IP  - 4
DP  - 2021 Apr
TI  - Prevalence of positive IGRAs and innate immune system in HIV-infected individuals 
      in Japan.
PG  - 592-597
LID - S1341-321X(20)30419-0 [pii]
LID - 10.1016/j.jiac.2020.11.012 [doi]
AB  - INTRODUCTION: Human immunodeficiency virus (HIV) infected individuals are at 
      increased risk of developing active tuberculosis (TB). TB incidence remains 
      higher than in non-HIV subjects after antiretroviral therapy (ART) initiation. 
      This study was conducted to estimate the prevalence of positive IGRA, reflecting 
      latent tuberculosis infection and/or a history of active TB, in HIV-infected 
      individuals after ART initiation in Japan. METHODS: Two IGRAs (Interferon (IFN)-gamma 
      release assays), QuantiFERON(R)-TB Gold Plus (QFT-Plus) and T-Spot(R).TB (TSPOT), 
      were used. We also analyzed the TB associated risk factors for the IGRAs results 
      and the role of CD4(+) T-cells, CD8(+) T-cells and NK cells for producing IFN-gamma. 
      We also analyzed the risk factors for positive IGRA responses and the role of 
      CD4(+) T-cells, CD8(+) T-cells and NK cells for producing IFN-gamma. RESULTS: One 
      hundred eight-four subjects were prospectively enrolled. Median age was 49 years. 
      The positivity rates of QFT-Plus and TSPOT were 7.6% [95%CI 4.6-12.4] and 2.7% 
      [95%CI 1.2-6.2], respectively, with significant difference. TB-associated risk 
      factors and NK cells >/=300/muL were selected as independently significant factors 
      by multivariate logistic regression. The NK cell count revealed significant 
      linear regression with IFN-gamma production responding to TB-specific antigens. 
      CONCLUSIONS: The prevalence of positive IGRAs was 2.7%-7.6%. QFT-Plus would be 
      practical for a higher positivity rate and reflect TB risk factors. The innate 
      immune system, referring to IFN-gamma production, plays an important role in the 
      immune response to TB-specific antigens even after initiating ART.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Igari, Hidetoshi
AU  - Igari H
AD  - Division of Infection Control, Chiba University Hospital, 1-8-1 Inohana Chuo-Ku, 
      Chiba, 260-8677, Japan. Electronic address: igari_h@chiba-u.jp.
FAU - Takayanagi, Shin
AU  - Takayanagi S
AD  - Division of Infection Control, Chiba University Hospital, 1-8-1 Inohana Chuo-Ku, 
      Chiba, 260-8677, Japan. Electronic address: shin-takayanagi@chiba-u.jp.
FAU - Yahaba, Misuzu
AU  - Yahaba M
AD  - Division of Infection Control, Chiba University Hospital, 1-8-1 Inohana Chuo-Ku, 
      Chiba, 260-8677, Japan. Electronic address: mis_misuzu@yahoo.co.jp.
FAU - Tsuyuzaki, Mizue
AU  - Tsuyuzaki M
AD  - Chiba Foundation for Health Promotion and Disease Prevention, 32-14 Shin-Minato 
      Mihama-ku, Chiba, 261-0002, Japan. Electronic address: 
      mi-tsuyuzaki@kenko-chiba.or.jp.
FAU - Taniguchi, Toshibumi
AU  - Taniguchi T
AD  - Division of Infection Control, Chiba University Hospital, 1-8-1 Inohana Chuo-Ku, 
      Chiba, 260-8677, Japan. Electronic address: tosh-tanig@chiba-u.jp.
FAU - Suzuki, Kiminori
AU  - Suzuki K
AD  - Chiba Foundation for Health Promotion and Disease Prevention, 32-14 Shin-Minato 
      Mihama-ku, Chiba, 261-0002, Japan. Electronic address: kimi.suzuki@nifty.com.
LA  - eng
PT  - Journal Article
DEP - 20201230
PL  - Netherlands
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
SB  - IM
MH  - CD8-Positive T-Lymphocytes
MH  - *HIV Infections/drug therapy/epidemiology
MH  - Humans
MH  - Interferon-gamma Release Tests
MH  - Japan/epidemiology
MH  - *Latent Tuberculosis
MH  - Middle Aged
MH  - *Mycobacterium tuberculosis
MH  - Prevalence
MH  - Tuberculin Test
OTO - NOTNLM
OT  - HIV
OT  - Innate immune system
OT  - Latent tuberculosis infection
OT  - NK cell
OT  - QuantiFERON-TB Gold plus
OT  - T-spot.TB
COIS- Declaration of competing interest None declared.
EDAT- 2021/01/03 06:00
MHDA- 2021/06/25 06:00
CRDT- 2021/01/02 05:15
PHST- 2020/09/17 00:00 [received]
PHST- 2020/10/17 00:00 [revised]
PHST- 2020/11/10 00:00 [accepted]
PHST- 2021/01/03 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2021/01/02 05:15 [entrez]
AID - S1341-321X(20)30419-0 [pii]
AID - 10.1016/j.jiac.2020.11.012 [doi]
PST - ppublish
SO  - J Infect Chemother. 2021 Apr;27(4):592-597. doi: 10.1016/j.jiac.2020.11.012. Epub 
      2020 Dec 30.